Interview with Mikel Arriola, Federal Commisioner, COFEPRIS
It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge…
Regenerative medicine aims to replace or regenerate damaged cells, tissues, or organs, both structurally and functionally, which have lost their optimal biological regulatory condition. Regeneration in nature can occur at the cellular, tissue, organ, structural, and even whole body levels, but in humans is naturally significantly limited with aging.
To achieve a transformational level of technological advancement in this area for humans, RegenerAge is utilizing novel combination applications of biological interventions, including stem cells, soluble regenerative biologics, proprietary nutritional bio-products, functional and regenerative based diets, bioidentical hormone replacement, and skin / aesthetic rejuvenation tools, yielding an unprecedented, integrated option for activating the natural healing processes of the body and maintaining health and wellness.
Regenerative medicine incorporates various fields of science, including genetics, biomedical engineering, tissue engineering, advanced cell technology, and evolutionary dynamics, with the goal of allowing human bodies to recover cellular function, vitality and optimizing its integrated operation.
Smart prevention is the best initial approach for any disease, but once an illness manifests as part of a person’s life, regeneration and repair are invaluable options to restore health and restructure damaged tissues and cells within the human body. Recent biotechnology related advances present wonderful opportunities for RegenerAge to improve outcomes when patients need more than traditional treatments, as well as to increase lifespan and wellness for those conscious about their health and longevity.
RegenerAge is open to working with all types of patients according to their medical status. Our treatments may help patients who suffer from a variety of chronic degenerative diseases including, but not limited to: cardiovascular conditions, diabetes, kidney damage, different types of cancer, auto-immune diseases, CNS degeneration, and hematological disorders.
Contact
Address: BNY Mellon Center 1735 Market Street, Suite 3750 Philadelphia PA 19103 USA
Tel. +52 55 3028 4783
Website: https://regenerage.clinic/es/
It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge…
Can you tell us a little about the history of Medix and about the company itself? Medix is a 100% Mexican company created in 1956, and our major strength is…
Apotex has increased production, launched 16 new products last March, and grown significantly in the market. What would you say has been the biggest change in the market over the…
The last time we interviewed you was in 2008. Please can you tell our readers a little bit more about Liomont’s growth drivers and changes over these last four years?…
When we saw you in 2008 we had read a little bit about the major milestones in the company, how your grandfather came to Mexico in the 1950s and how…
Please can you tell our readers a little bit more about the history of Stendhal, and its major milestones along the way since its takeover in 1997? Stendhal is a…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Big news last year; Takeda bought Nycomed in what has been seen as a game changing acquisition for the pharma world. How have you seen this acquisition affect Nycomed’s Latin…
The Mexican government has been fairly pro-active about promoting good practice such as the new drug registration process that helped eliminate drugs from the Mexican market that didn’t fulfill regulatory…
There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local plant rule. COFEPRIS has…
This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last interviewed you in 2008?…
This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be…
See our Cookie Privacy Policy Here
